Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)

SAN DIEGO & PALO ALTO, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934. Acer is a pharmaceutical company that focuses on the development and commercialization of therapies for rare diseases. One of its medications is EDVISO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome ("vEDS").

If you suffered a loss as a result of Acer's misconduct, click here.

Acer Therapeutics Inc. (ACER) Accused of Misleading Investors

Since the Company’s founding in 2013, Acer has allocated much of its resources into EDSIVO, including funding research and clinical studies into the efficacy of the drug in the hopes of obtaining U.S. Food and Drug Administration (“FDA”) approval for the drug. To help fund this research, Acer conducted two secondary public offerings in December 2017 and August 2018. In each of these offerings, Acer touted EDVISO's future prospects and assured that EDVISO's New Drug Application ("NDA") would be approved, citing data gathered from a French clinical trial published in October 2010 involving the use of celiprolol (the “Ong Trial”). However, on June 25, 2019, Acer revealed that the Company had received a response letter from the FDA stating Acer would need to "conduct an adequate and well-controlled trial" to accurately determine the efficacy of EDVISO in treating vEDS to receive FDA approval. Reports later revealed that the small group size of the Ong Trial that supported the NDA raised questions about the adequacy of EDVISO's trial results. On this news, Acer's stock price fell nearly 79% to close at $4.12. To date, none of Acer's drug candidates has received FDA approval.

Acer Therapeutics Inc. (ACER) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
[phone]
[e-mail]
Shareholder Information Form

Want to be notified if a class action against Acer settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.